RIBOMIC completes patient enrollment in early phase II study of umedaptanib pegol for Achondroplasia

RIBOMIC Inc., a Tokyo-based leader in aptamer therapeutics, has reported significant progress in its early phase II study of umedaptanib pegol. This breakthrough involves treating ... Read More